Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
about
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugEvaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue SarcomasVorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK PathwaysInsulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.New strategies in ewing sarcoma: lost in translation?A framework for genomic biomarker actionability and its use in clinical decision makingMorphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1)Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumorsTargeted therapies for advanced Ewing sarcoma family of tumors.Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatmentTargeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicineAntitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.Ewing's sarcoma: overcoming the therapeutic plateau.Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphomaTargeted therapy for sarcomas.Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsDefining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.Targeted therapy in rare cancers--adopting the orphans.Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions.Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.Debunking the Delusion That Precision Oncology Is an Illusion.The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.Exceptional responders: in search of the science behind the miracle cancer cures.Challenging Standard-of-Care Paradigms in the Precision Oncology Era.The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Al
P2860
Q27025344-C7AE1FC8-5B18-4CF1-977F-950E1E271CBBQ28538155-781A33CE-B40D-4CB6-9086-9CF0626B065EQ28548425-AD3E2629-5591-4B41-BB0B-796B3D1E99C8Q28550980-452EF0C4-2845-4EED-B703-5EC511C139ADQ33400495-4316964A-FE55-49E6-8F48-1028E798F22DQ33758471-A41293F3-033C-443A-AB30-A96559897A74Q34781122-3649061A-DCF5-447C-BE87-9BE65C84B41EQ34901968-0530FD26-32F3-45EF-A6C1-52CDC63B486DQ35224188-6C7271A8-C553-4CFB-B725-5872997C7C1FQ35589492-39B0158A-A45E-48AB-B8BE-7C24CE445EFCQ35850208-9F81170F-1875-4648-94CA-8D670FBE4A04Q36131601-01DCD396-37EA-4A31-9BCB-527031205ADAQ36392814-6EB408B8-EBBC-4F5B-B0AF-28B76256D8D0Q36562114-8FA70B6B-FD93-46F0-B12D-21586D211C51Q36665125-EB9C4450-DB08-4F47-BB4F-54BB90734646Q37132240-6A47DB4F-A147-4AD5-8E56-10E6F50C3786Q37204286-4209200F-6CFE-4A8B-BC3C-BC688912F22CQ37342909-2B7753BC-3EE4-4EBE-8FEF-EE5F3F1F0A4AQ37487126-16AED01E-B44F-4EF9-BE2F-F9CB0E4C1794Q37496876-5CD31CC9-A5C8-4501-8F6F-F12F811C8FE7Q37649637-74D2F62D-5AB9-4F12-84E8-A350730C104FQ37655450-F9BA4286-0C9E-413A-B94C-072F9EB53067Q37665702-8623C7CC-60EA-4065-A4EE-0D17AB29C216Q37729968-3B3832A4-CEDD-403D-9950-BB7B728A5397Q37903335-4B7719DE-2A8B-4902-A31A-97A1B3DA3A69Q37990768-3A62FFD9-33CE-4C1F-8FE5-B62AB6759CC5Q38042324-DAEBF2EC-503C-4E22-9C89-BEE8B9E83997Q38243878-3CFBBBDD-734D-49B8-AD47-DC3DE3FB697EQ38748961-15018E6D-1FF5-48D8-9434-5D73B0F2B144Q39328101-617AB526-E1F2-41F0-8E01-A24410AABE27Q39618772-36800334-2802-4D99-97CC-3C021475A884Q44727423-0ED0BF01-0F82-4974-80FB-4414B4FD1493Q45743838-6280AF1F-BF6C-4AE1-B29B-5A3E840763A2Q46451484-816D3056-8AF8-4A65-A85B-11B004AB6246Q46539715-E994AFC9-3312-4242-8805-AB97377063F8Q48173183-ED477FBA-58FC-48F1-9F14-963F840FABB9Q48639229-DE174B29-310A-4380-B7DE-22650E45DB3AQ49835188-75FED474-1821-477D-9227-AF850CB21F9BQ50067454-752F71A2-8144-4CA4-A815-DFDCCA641499Q54355019-858E126F-AA8F-4DC9-8EF2-36E5F4D3AD01
P2860
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Targeted morphoproteomic profi ...... esponse/resistance signatures.
@ast
Targeted morphoproteomic profi ...... esponse/resistance signatures.
@en
type
label
Targeted morphoproteomic profi ...... esponse/resistance signatures.
@ast
Targeted morphoproteomic profi ...... esponse/resistance signatures.
@en
prefLabel
Targeted morphoproteomic profi ...... esponse/resistance signatures.
@ast
Targeted morphoproteomic profi ...... esponse/resistance signatures.
@en
P2093
P2860
P1433
P1476
Targeted morphoproteomic profi ...... esponse/resistance signatures.
@en
P2093
Helen Chen
Laurence Doyle
Patricia LoRusso
Pete Anderson
Robert Benjamin
Robert E Brown
Vivek Subbiah
P2860
P304
P356
10.1371/JOURNAL.PONE.0018424
P407
P577
2011-04-06T00:00:00Z